FIT Biotech Oy: FIT Biotech’s FIT-06 phase 1 HIV clinical trial results published

Company release 19.12.2017 at 09.30 EET

FIT Biotech’s FIT-06 phase 1 HIV clinical trial results published
FIT Biotech Oy (the “company”) announced today the publication of the results of the phase 1 CUTHIVAC-001 clinical trial. The trial demonstrated that FIT-06 is safe and well-tolerated, and gives the desired immune response. These results are essential for the advancement of the company’s HIV vaccine program. 

The results were published in the scientific journal Scientific Reports under the title “Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial.” The FIT-06 will next be tested in a multinational phase 2 clinical trial on HIV-positive patients that have been given standard therapies. The upcoming trial is coordinated by the European HIV Vaccine Alliance and sponsored by the EU Horizon 2020 program. It is expected to begin in early 2018.

Professor Robin Shattock, who led the team at Imperial College London that conducted the clinical trial said, “We are encouraged by these results as they contribute to the advancement of our programs for nucleic acid vaccines, including those for HIV.  The next step will be to determine whether this vaccine approach can modify responses in individuals infected with HIV.”

FIT Biotech’s CEO James Kuo comments: “Publication of these clinical trial results are tangible evidence of the high-quality science we perform with our partners, and demonstrates that we make steady progress towards developing a first-in-class vaccine against HIV.  The results also support our efforts to develop a broad range of safe and cost-effective gene-based therapies based on our proprietary GTU vector technology.”

Further information:
James Kuo
FIT Biotech Oy
Tel: +358 44 0331307

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programs. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.